Mineralys Therapeutics Inc (MLYS)

Finanzdaten der Mineralys Therapeutics Inc-Aktie (MLYS)

Gewinn- und Verlustrechnung

Vierteljährlich

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	-	-	-	-	-
Operating Expenses	27.61% 35.36	27.71	26.27	15.73	14.94
Operating Income/Loss	27.61% -35.36	-27.71	-26.27	-15.73	-14.94
Nonoperating Income/Loss	16.01% 3.854	3.322	3.513	3.594	2.33
Income/Loss From Continuing Operations Before Tax	29.19% -31.51	-24.39	-22.76	-12.14	-12.61
Income/Loss From Continuing Operations After Tax	29.19% -31.51	-24.39	-22.76	-12.14	-12.61
Net Income/Loss	29.19% -31.51	-24.39	-22.76	-12.14	-12.61
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	3,312% 44.90	1.316	39.93	39.75	24.76
Diluted Average Shares	3,312% 44.90	1.316	39.93	39.75	24.76
Basic Earnings Per Share	11.11% -0.70	-0.63	-0.57	-0.31	-0.51
Diluted Earnings Per Share	11.11% -0.70	-0.63	-0.57	-0.31	-0.51
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-